Submitted by:	Chief Medical Officer
Name:	Johnathan Lancaster, MD, PhD
Company/Organization:	Myriad Genetic Laboratories, Inc.
Address:	320 Wakara Way, Salt Lake City, UT 84108
Phone:	801-505-5090
Email:	jlancaster@myriad.com
Date of request:	October 10, 2016
NCCN Guidelines Panel:	Survivorship

Specific Changes: On page SURV-3, expand the details for genetic risk assessment, possibly breaking it out as a distinct sub-section of the discussion of Screening for Second Cancers. This section should 1) provide guidance regarding which patients are "appropriate candidates" for genetic risk assessment (i.e. patients whose diagnosis was at a relatively young age, or those with a family history of the same or other cancers), 2) emphasize the importance of regularly updating family history to identify emerging evidence of hereditary risk, and 3) remind providers of the necessity for ongoing review of available options for genetic testing in light of the rapid evolution of new testing technologies, including panels, and expanding knowledge of the basis of inherited risk.

FDA Clearance: Not applicable.

Rationale: The central importance of identifying genetic risk factors to guide the prevention of second cancers in survivors has been comprehensively reviewed by Ruddy et al., and detailed guidelines for genetic risk assessment and testing in cancer survivors are included in the ASCO Survivorship guidelines. There has been a steady improvement in the consistent application of existing testing guidelines for newly diagnosed patients, but the majority of cancer survivors today were diagnosed at a time when awareness, access and testing options were limited. The recent introduction of expanded multi-gene panels illustrates the need to address testing options on an ongoing basis with all cancer survivors to ensure that they are evaluated in light of evolving knowledge and guidelines.

The following articles are submitted in support of this proposed change. We would like to acknowledge the contributions of NCCN panel members who are also co-authors or co-contributors of some of these publications.

1. Ruddy KJ, Risendal BC, Garber JE, Partridge AH. Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. *J Clin Oncol*. 2016 Feb 20;34(6):539-41. Epub 2015 Dec 28. PMID: 26712228.

2. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *CA Cancer J Clin*. 2016 Jan-Feb;66(1):43-73. Epub 2015 Dec 7. Review. PMID: 26641959.

3. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. *Breast Cancer Res Treat*. 2016 Jan;155(1):165-73. Epub 2015 Dec 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):201. PMID: 26706041.

Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer, Myriad Genetic Laboratories Inc.